Literature DB >> 28346436

Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells.

D Hoffmann1,2,3, J W Schott1,2, F K Geis1,2, L Lange1,2, F-J Müller4, D Lenz1, D Zychlinski1, D Steinemann5, M Morgan1, T Moritz1,2, A Schambach1,2,3,6.   

Abstract

Correction of patient-specific induced pluripotent stem cells (iPSC) upon gene delivery through retroviral vectors offers new treatment perspectives for monogenetic diseases. Gene-modified iPSC clones can be screened for safe integration sites and differentiated into transplantable cells of interest. However, the current bottleneck is epigenetic vector silencing. In order to identify the most suitable retroviral expression system in iPSC, we systematically compared vectors from different retroviral genera, different promoters and their combination with ubiquitous chromatin opening elements (UCOE), and several envelope pseudotypes. Lentiviral vectors (LV) pseudotyped with vesicular stomatitis virus glycoprotein were superior to gammaretroviral and alpharetroviral vectors and other envelopes tested. The elongation factor 1α short (EFS) promoter mediated the most robust expression, whereas expression levels were lower from the potent but more silencing-prone spleen focus forming virus (SFFV) promoter. Both full-length (A2UCOE) and minimal (CBX3) UCOE juxtaposed to two physiological and one viral promoter reduced transgene silencing with equal efficiency. However, a promoter-specific decline in expression levels was not entirely prevented. Upon differentiation of transgene-positive iPSC into endothelial cells, A2UCOE.EFS and CBX3.EFS vectors maintained highest transgene expression in a larger fraction of cells as compared with all other constructs tested here. The function of UCOE diminished, but did not fully counteract, vector silencing and possibilities for improvements remain. Nevertheless, the CBX3.EFS in a LV background exhibited the most promising promoter and vector configuration for both high titer production and long-term genetic modification of human iPSC and their progeny.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28346436     DOI: 10.1038/gt.2017.20

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  53 in total

1.  Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming.

Authors:  Eva Warlich; Johannes Kuehle; Tobias Cantz; Martijn H Brugman; Tobias Maetzig; Melanie Galla; Adam A Filipczyk; Stephan Halle; Hannes Klump; Hans R Schöler; Christopher Baum; Timm Schroeder; Axel Schambach
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

2.  Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.

Authors:  Axel Schambach; Jens Bohne; Saurabh Chandra; Elke Will; Geoffrey P Margison; David A Williams; Christopher Baum
Journal:  Mol Ther       Date:  2005-10-12       Impact factor: 11.454

3.  Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates.

Authors:  Virginie Sandrin; Bertrand Boson; Patrick Salmon; Wilfried Gay; Didier Nègre; Roger Le Grand; Didier Trono; François-Loïc Cosset
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

4.  Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors.

Authors:  Julia D Suerth; Michael A Morgan; Stephan Kloess; Dirk Heckl; Christine Neudörfl; Christine S Falk; Ulrike Koehl; Axel Schambach
Journal:  J Mol Med (Berl)       Date:  2015-08-25       Impact factor: 4.599

5.  Improved retroviral episome transfer of transcription factors enables sustained cell fate modification.

Authors:  J W Schott; D Hoffmann; T Maetzig; F-J Müller; D Steinemann; D Zychlinski; T Cantz; C Baum; A Schambach
Journal:  Gene Ther       Date:  2014-08-07       Impact factor: 5.250

6.  Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells.

Authors:  Angel Raya; Ignasi Rodríguez-Pizà; Guillermo Guenechea; Rita Vassena; Susana Navarro; María José Barrero; Antonella Consiglio; Maria Castellà; Paula Río; Eduard Sleep; Federico González; Gustavo Tiscornia; Elena Garreta; Trond Aasen; Anna Veiga; Inder M Verma; Jordi Surrallés; Juan Bueren; Juan Carlos Izpisúa Belmonte
Journal:  Nature       Date:  2009-05-31       Impact factor: 49.962

7.  Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing.

Authors:  Michael Antoniou; Lee Harland; Tracey Mustoe; Steven Williams; Jolyon Holdstock; Ernesto Yague; Tony Mulcahy; Mark Griffiths; Sian Edwards; Panayiotis A Ioannou; Andrew Mountain; Robert Crombie
Journal:  Genomics       Date:  2003-09       Impact factor: 5.736

8.  Stable gene expression occurs from a minority of integrated HIV-1-based vectors: transcriptional silencing is present in the majority.

Authors:  H P Mok; S Javed; A Lever
Journal:  Gene Ther       Date:  2007-03-01       Impact factor: 5.250

9.  A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells.

Authors:  Uta Müller-Kuller; Mania Ackermann; Stephan Kolodziej; Christian Brendel; Jessica Fritsch; Nico Lachmann; Hana Kunkel; Jörn Lausen; Axel Schambach; Thomas Moritz; Manuel Grez
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

10.  Embryonic stem cells use ZFP809 to silence retroviral DNAs.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Nature       Date:  2009-03-08       Impact factor: 49.962

View more
  14 in total

Review 1.  Gene delivery methods and genome editing of human pluripotent stem cells.

Authors:  Patrycja Czerwińska; Sylwia Mazurek; Iga Kołodziejczak; Maciej Wiznerowicz
Journal:  Rep Pract Oncol Radiother       Date:  2019-02-18

2.  Luminescent Human iPSC-Derived Neurospheroids Enable Modeling of Neurotoxicity After Oxygen-glucose Deprivation.

Authors:  Elise Van Breedam; Aleksandra Nijak; Tamariche Buyle-Huybrecht; Julia Di Stefano; Marlies Boeren; Jonas Govaerts; Alessandra Quarta; Tine Swartenbroekx; Eva Z Jacobs; Björn Menten; Rik Gijsbers; Peter Delputte; Maaike Alaerts; Behrouz Hassannia; Bart Loeys; Zwi Berneman; Jean-Pierre Timmermans; Philippe G Jorens; Tom Vanden Berghe; Erik Fransen; An Wouters; Winnok H De Vos; Peter Ponsaerts
Journal:  Neurotherapeutics       Date:  2022-03-14       Impact factor: 6.088

3.  Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

Authors:  Alec J Walker; Robbie G Majzner; Ling Zhang; Kelsey Wanhainen; Adrienne H Long; Sang M Nguyen; Paola Lopomo; Marc Vigny; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Mol Ther       Date:  2017-07-01       Impact factor: 11.454

4.  Cytokine Selection of MSC Clones with Different Functionality.

Authors:  Anton Selich; Teng-Cheong Ha; Michael Morgan; Christine S Falk; Constantin von Kaisenberg; Axel Schambach; Michael Rothe
Journal:  Stem Cell Reports       Date:  2019-07-11       Impact factor: 7.765

5.  High-Throughput Phenotypic Assay for Compounds That Influence Mitochondrial Health Using iPSC-Derived Human Neurons.

Authors:  Courtney MacMullen; Ronald L Davis
Journal:  SLAS Discov       Date:  2021-03-16       Impact factor: 3.341

6.  Lentiviral Hematopoietic Stem Cell Gene Therapy Rescues Clinical Phenotypes in a Murine Model of Pompe Disease.

Authors:  Giuseppa Piras; Claudia Montiel-Equihua; Yee-Ka Agnes Chan; Slawomir Wantuch; Daniel Stuckey; Derek Burke; Helen Prunty; Rahul Phadke; Darren Chambers; Armando Partida-Gaytan; Diego Leon-Rico; Neelam Panchal; Kathryn Whitmore; Miguel Calero; Sara Benedetti; Giorgia Santilli; Adrian J Thrasher; H Bobby Gaspar
Journal:  Mol Ther Methods Clin Dev       Date:  2020-07-06       Impact factor: 6.698

Review 7.  Corneal cell therapy: with iPSCs, it is no more a far-sight.

Authors:  Koushik Chakrabarty; Rohit Shetty; Arkasubhra Ghosh
Journal:  Stem Cell Res Ther       Date:  2018-10-25       Impact factor: 6.832

8.  Inducible Forward Programming of Human Pluripotent Stem Cells to Hemato-endothelial Progenitor Cells with Hematopoietic Progenitor Potential.

Authors:  Lucas Lange; Dirk Hoffmann; Adrian Schwarzer; Teng-Cheong Ha; Friederike Philipp; Daniela Lenz; Michael Morgan; Axel Schambach
Journal:  Stem Cell Reports       Date:  2019-12-12       Impact factor: 7.765

9.  Rosa26 docking sites for investigating genetic circuit silencing in stem cells.

Authors:  Michael Fitzgerald; Mark Livingston; Chelsea Gibbs; Tara L Deans
Journal:  Synth Biol (Oxf)       Date:  2020-08-19

10.  Genetic Correction of IL-10RB Deficiency Reconstitutes Anti-Inflammatory Regulation in iPSC-Derived Macrophages.

Authors:  Dirk Hoffmann; Johanna Sens; Sebastian Brennig; Daniel Brand; Friederike Philipp; Philippe Vollmer Barbosa; Johannes Kuehle; Doris Steinemann; Daniela Lenz; Theresa Buchegger; Michael Morgan; Christine S Falk; Christoph Klein; Nico Lachmann; Axel Schambach
Journal:  J Pers Med       Date:  2021-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.